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Introduction {#sec1}
============

Vascular calcification is a major complication in aging populations and patients with chronic kidney disease (CKD), who display characteristics of premature aging ([@bib29], [@bib30], [@bib38], [@bib67]). Vascular calcification is highly associated with cardiovascular mortality ([@bib5], [@bib6]). Recent studies revealed that saturated fatty acids (SFAs) contribute to the development of vascular calcification by promoting vascular apoptosis and transdifferentiation of vascular smooth muscle cells (VSMCs) to osteoblastic-like cells ([@bib12], [@bib61]). "Lipotoxicity" of excess SFAs is manifested as apoptosis, endoplasmic reticulum (ER) stress, or production of oxidative stress that accelerates vascular calcification ([@bib3], [@bib7], [@bib44]). Stearoyl-CoA desaturase (SCD) catalyzes the conversion of SFAs to unsaturated fatty acids (UFAs) by introducing a double bond at the Δ9 position ([@bib50]). In our previous *in vivo* and *in vitro* studies, SCD inhibition induced vascular calcification and cell apoptosis associated with excess accumulation of metabolites of SFAs in VSMCs ([@bib43]). Using lipidomic and shRNA screening approaches, we identified three acyltransferases, glycerol-3-phosphate acyltransferase-4 (GPAT4), and acylglycerol-3-phosphate acyltransferase-3 and -5 (AGPAT3 and AGPAT5), that mediate SFA-induced ER stress and vascular calcification by generating fully saturated phosphatidic acids (PAs) such as distearoyl-phosphatidic acid in VSMCs. Importantly, two recent bias studies have confirmed our observations that GPAT4 is a central enzyme mediating SFA-induced global cellular lipotoxicity ([@bib59], [@bib81]). However, whether other lipotoxic pathways and other SFA metabolites generated through GPAT4 contribute to vascular calcification is still obscure.

The autophagy-related gene (ATG) family generates the autophagosome membrane ([@bib11], [@bib51]). During the activation state of autophagy, the phosphatidylinositol 3-kinase VPS34 and Beclin-1 complex is recruited to the ER-mitochondria contact site, the mitochondria-associated membrane (MAM) ([@bib17]), and generates phosphatidylinositol 3-phosphate (PI3P) as an early event of autophagy ([@bib22], [@bib45], [@bib68], [@bib80]). PI3P-enriched ER membrane, known as the origin for autophagosome membrane formation, can be visualized by specific PI3P-binding proteins such as double FYVE domain-containing protein-1 (DFCP1) and WD repeat domain phosphoinositide-interacting protein-2 (WIPI2), which are positive membranes called "omegasomes" whose structure is shaped as the letter "Ω" ([@bib4], [@bib60]). Omegasomes are a platform to form isolation membranes (an autophagosomal precursor) that are unclosed autophagosome membrane structures visualized by either LC3 or ATG16L1 in combination with omegasome markers such as WIPI2 and DFCP1 ([@bib4], [@bib23], [@bib60]). When the omegasome structure is deformed by inhibition of the capping protein (CapZ)-dependent actin filament assembly, the abnormal isolation membrane structure accumulates DFCP1-positive elongated membrane structures ([@bib48]). However, metabolites that can affect the omegasome structure are still not identified. LC3 is conjugated to the PE molecule on the isolation membrane as lipidated LC3 (LC3-II) by the ATG12-ATG5-ATG16 complex, similar to ubiquitin conjugation after cleavage of glycine 120 residue of LC3 by ATG4 ([@bib14], [@bib20], [@bib24], [@bib46], [@bib52], [@bib71]). The isolation membrane matures to an autophagosome with a double membrane structure while loading autophagic cargo such as Sequestosome-1 (p62) or damaged mitochondria ([@bib11], [@bib78]). The mature autophagosome then fuses with a lysosome to generate autolysosomes for degradation inside of Lc3-II and cargo proteins ([@bib15], [@bib31]). Inhibition of autophagy machinery such as an autophagosome-lysosome fusion or protein degradation in autolysosomes induces accumulation of Lc3-II and autophagic substrates ([@bib78]). Because a number of membrane formations and modulations are involved in autophagy machinery, phospholipid modulations such as PI3P and PE are known to affect autophagic flux ([@bib49], [@bib58], [@bib65]). Besides their role in phospholipids, fatty acyl chains are involved in autophagic machinery. For instance, SCD contributes to autophagosome formation at an early stage of autophagy initiation through an unknown mechanism ([@bib55]). In addition, there are a number of studies showing that saturated and unsaturated fatty acids (SFAs and UFAs) modulate autophagy ([@bib9], [@bib33], [@bib47], [@bib69]), although a precise conclusion has not been made due to the lack of a detailed mechanistic study. In addition, emerging evidence suggests that the modulation of autophagy contributes to lipotoxicity-mediated diseases such as vascular calcification ([@bib34], [@bib35], [@bib54], [@bib66], [@bib74]). Inhibition of autophagy by phosphatidylinositol 3-kinase (PI3K) inhibitor worsens inorganic phosphate (Pi)-induced vascular calcification through secretion of matrix vesicles with alkali phosphatase ([@bib10]), whereas an activator of autophagy, rapamycin, inhibits vascular calcification ([@bib79]). CKD induces the accumulation of aortic Lc3-II ([@bib10]). However, there is no direct evidence that autophagy plays a causative or protective role in regulating vascular calcification *in vivo*.

In this study, we present evidence that SFA-mediated autophagy inhibition contributes to lipotoxicities including vascular calcification and apoptosis and identify the mechanisms by which SFAs mediate autophagic flux.

Results {#sec2}
=======

Saturated Fatty Acids Induced Accumulation of Lipidated Lc3 and p62 in Mouse Aortas and Cultured Vascular Smooth Muscle Cells {#sec2.1}
-----------------------------------------------------------------------------------------------------------------------------

Smooth muscle cell (SMC)-specific SCD1/2 deficiency induced severe medial calcification, consistent with our previous report ([@bib43]) ([Figure S1](#mmc1){ref-type="supplementary-material"}A and S1B). Because recent studies suggest that autophagy contributes to vascular calcification, we examined levels of Lc3b-II and p62 proteins in the aortas from SMC-*Scd1/2* knockout (KO) mice by immunoblot analysis ([Figure 1](#fig1){ref-type="fig"}A). *Scd1/2* KO induced accumulation of lipidated Lc3b (Lc3b-II) and p62 proteins. Immunofluorescence analysis revealed a significant increase in Lc3 punctation in the aortas of SMC-*Scd1/2* KO mice ([Figure 1](#fig1){ref-type="fig"}B). In addition, another mouse model with vascular calcification, mice with 5/6 nephrectomy ([Figure S1](#mmc1){ref-type="supplementary-material"}C), also had significantly higher protein levels of the aortic autophagy substrates Lc3b-II and p62 than sham-operated control mice ([Figure S1](#mmc1){ref-type="supplementary-material"}D). These results suggest that SMC-specific *Scd1/2* KO and CKD modulate autophagic flux *in vivo*. To examine the effect of fatty acids on autophagy in VSMCs, we treated VSMCs with 15 major fatty acids in mammals and analyzed levels of Lc3b and p62 proteins under nutrient-rich (complete media) and starvation (EBSS) conditions ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}E). SFAs such as palmitic (C16:0), stearic (C18:0), and arachidic (C20:0) acids but no unsaturated fatty acids (UFAs) induced accumulation of Lc3b-II and p62. Levels of Lc3b-II and p62 were dose-dependently increased by treatment with C18:0 under both nutrient-rich and starvation (EBSS) conditions ([Figure 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}F). Treatment with CAY10566 (an SCD-specific inhibitor) potentiated the effect of C18:0 on autophagy in VSMCs ([Figure 1](#fig1){ref-type="fig"}E). Consistent with the immunoblot analysis, treatment of VSMCs with C18:0 significantly increased the number of Lc3 puncta ([Figures 1](#fig1){ref-type="fig"}F and 1G). In addition, GFP-p62-stable VSMCs treated with SFAs and SCD inhibitor but not UFAs significantly induced accumulation of GFP-p62 puncta ([Figures S1](#mmc1){ref-type="supplementary-material"}G and S1H). Similar to VSMCs, treatment with C18:0 in various cell lines such as NIH3T3 and HeLa also induced accumulation of Lc3b-II and p62 ([Figures S1](#mmc1){ref-type="supplementary-material"}I and S1J). To further analyze the effect of SFA-induced autophagy inhibition, we assessed ER-phagy. C18:0 blocked starvation-induced degradation of ER-phagy receptor proteins such as Testis-expressed 264 (Tex264) ([@bib2], [@bib8]) and Fam134b ([@bib26], [@bib28]), accompanied by accumulation of Lc3b-II ([Figure S1](#mmc1){ref-type="supplementary-material"}K).Figure 1Saturated Fatty Acids (SFAs) Inhibited Autophagic Flux in Mouse Models and Cultured Vascular Smooth Muscle Cells (VSMCs)(A) Immunoblot analysis of aortic media of control and smooth muscle cell (SMC)-specific *Scd1/2* knockout (KO) mice.(B) Confocal microscopy merged images of alpha-smooth muscle actin (aSMA, green), Lc3 (red), and DAPI (blue) in aortas of control and SMC-*Scd1/2* KO mice with CKD. Scale represents 50 μm. Arrow indicates Lc3 punctation.(C) Immunoblot analysis of human VSMCs treated with 250 μM of 15 major saturated or unsaturated fatty acids for 6 h.(D) Dose-dependent effect of C18:0 (SFA) on Lc3b and p62 proteins.Immunoblot analysis of VSMCs treated with C18:0 for 6 h.(E) Immunoblot analysis of VSMCs treated with C18:0 and 3 μM CAY10566 for 6 h.(F) Immunofluorescence of Lc3 (red) and DAPI (blue) in VSMCs treated with vehicle or 200 μM C18:0 for 2 h.(G) Number of Lc3 puncta in [Figure 1](#fig1){ref-type="fig"}F (n = 25, 2-tailed Student\'s t test). ∗p \< 0.05. Data are represented as mean ± SEM.(H) Scheme of measurement of autophagic flux with GFP-LC3-RFP-LC3ΔG probe.(I) Measurement of autophagic flux using stable VSMCs expressing GFP-LC3-RFP-LC3ΔG co-treated with Veh, 300 μM C16:0, C16:1, C18:0, C18:1, or 200 nM bafilomycin A1 under EBSS conditions for 6 h. GFP/RFP ratio data were expressed as fold value against Veh (n = 4, One-way ANOVA). ∗p \< 0.05.(J) Measurement of autophagic flux in stable VSMCs expressing GFP-LC3-RFP-LC3ΔG treated with C18:0 or bafilomycin A1 under EBSS conditions for 6 h (n = 4).

SFAs Block Autophagic Flux {#sec2.2}
--------------------------

SFAs induced accumulation of Lc3b-II and p62. Accumulation of Lc3b-II possibly occurs by both induction and inhibition of autophagy. We next examined whether SFAs either induce or inhibit autophagic flux using an autophagy probe, the GFP-LC3-RFP-LC3ΔG probe ([@bib25]). The probe is cleaved by Atg4 under autophagy induction and divided into GFP-LC3 and RFP-LC3ΔG. GFP-LC3 conjugates with PE on an isolation membrane through glycine 120 residue. After autophagosome-lysosome fusion, interior GFP-LC3 is degraded and GFP fluorescence is diminished by the acidic environment of the autolysosome. Because RFP-LC3ΔG cannot be degraded by incapability of conjugation to PE due to deletion of glycine 120, RFP fluorescence can be used as internal control due to its stability. A decline of the GFP/RFP ratio indicates autophagic flux ([Figure 1](#fig1){ref-type="fig"}H). To examine the effect of fatty acids on autophagic flux, VSMCs stably expressing GFP-LC3-RFP-LC3ΔG were treated with SFAs and UFAs. Treatment with SFAs such as C16:0 and C18:0 but not UFAs such as C16:1 and C18:1 dose-dependently increased the GFP/RFP ratio compared with vehicle ([Figures 1](#fig1){ref-type="fig"}I and 1J). These results conclude that SFAs block autophagic flux, resulting in significant accumulation of autophagic substrates such as Lc3b-II and p62 in VSMCs.

Inhibition of Autophagy Induces Mortality and Vascular Calcification in CKD {#sec2.3}
---------------------------------------------------------------------------

Because SFAs inhibit autophagic flux, we next examined whether inhibition of autophagy induces vascular calcification. In VSMC cultures, *Atg5* KO significantly induced mineralization of VSMCs ([Figures 2](#fig2){ref-type="fig"}A, 2B, and [S2](#mmc1){ref-type="supplementary-material"}A). We next generated SMC-specific *Atg5* KO mice to study the effect of Atg5 on the development of autophagy in CKD *in vivo*. The deletion of the gene of interest was observed in smooth muscle cells but no other cells, as previously reported ([Figure 2](#fig2){ref-type="fig"}C and data not shown). As expected, SMC-Atg5 deficiency blocked Lc3b lipidation, blocking autophagy and inducing p62 accumulation ([Figure 2](#fig2){ref-type="fig"}C) in the aortic media. To study CKD-dependent vascular calcification, CKD was induced by 5/6 nephrectomy. Interestingly, CKD drastically shortened the life span of SMC-specific *Atg5* KO mice ([Figure 2](#fig2){ref-type="fig"}D) without affecting levels of serum creatinine, phosphorus, or calcium ([Figures S2](#mmc1){ref-type="supplementary-material"}B--S2D). More importantly, SMC-Atg5 deficiency significantly aggravated aortic medial calcification ([Figures 2](#fig2){ref-type="fig"}E--2G) and apoptosis ([Figures 2](#fig2){ref-type="fig"}H and 2I) and damaged mitochondria accumulation ([Figures 2](#fig2){ref-type="fig"}J) 6 weeks after CKD induction.Figure 2Deficiency of *Atg5*-Dependent Autophagy in Smooth Muscle Cells (SMCs) Induced Death at a High Mortality Rate, Severe Calcification, and Apoptosis in 5/6 Nephrectomized Mice(A) Mineralization of scrambled sg (control) or *Atg5* knockout (KO) VSMCs treated with 2.6 mM Pi every 2 days for 6 days. (n = 6, 2-tailed Student\'s t test) ∗p \< 0.05. Data are represented as mean ± SEM.(B) Alizarin red staining of control and Atg5 knockout VSMCs treated with Pi for 6 days.(C) Immunoblot analysis of aortic medias from control and SMC-Atg5 KO mice.(D) Survival rate of control and SMC-*Atg5* KO mice after 5/6 nephrectomy (n = 20, log rank and Wilcoxon signed rank method) ∗p \< 0.05.(E) Photograph (x10 magnification) of the lesions of aortic sinuses with von Kossa staining in control and SMC-*Atg5* KO mice with CKD. Scale represents 50 μm.(F) Quantitative analysis of aortic calcified regions (n = 8, 2-tailed Student\'s t test). ∗∗∗p \< 0.001. Data are represented as mean ± SEM.(G) Aortic calcium content (n = 8, one-way ANOVA). ∗∗p \< 0.01, ∗∗∗p \< 0.001. Data are represented as mean ± SEM.(H) Photograph of TUNEL staining (magenta) and DAPI (blue) from aortas of control and SMC-*Atg5* KO mice with CKD. Scale represents 50 μm.(I) Quantitative analysis of TUNEL-positive nuclei in aortic lesions (n = 8, 2-tailed Student\'s t test). ∗∗∗p \< 0.001. Data are represented as mean ± SEM.(J) Electron micrograph of aortic lesions in control and SMC-*Atg5* KO mice with CKD. Scale represents 1 μm. SMC, smooth muscle cells; EC, endothelial cells; AP, autophagosome; Mt, mitochondria.

SFAs Inhibit Starvation-Induced Autophagy at Steps Prior to Degradation in Autolysosomes {#sec2.4}
----------------------------------------------------------------------------------------

Because SFAs inhibit autophagic flux, we put in extensive efforts to elucidate the precise mechanism by which SFAs block autophagy. To enhance the effect of SFAs on autophagy, we performed all of the mechanistic studies under starvation conditions with EBSS treatment. We first performed confocal microscopic analysis with co-immunostaining of Lc3 and Lamp1 to assess whether SFAs affect lysosomal function ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Treatment of VSMCs with SFAs such as C18:0 exhibited significant accumulation of Lc3 compared with vehicle ([Figure S3](#mmc1){ref-type="supplementary-material"}B), but co-localization of Lc3 and Lamp1 was not increased ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Treatment with SCD inhibitor (CAY) also increased total Lc3 but not co-localization of Lc3 and Lamp1, similar to C18:0 treatment. In contrast, treatment with various lysosomal inhibitors such as the protease inhibitors leupeptin, pepstatin A, and bafilomycin A1 increased co-localization of Lc3 and Lamp1 in VSMCs ([Figure S3](#mmc1){ref-type="supplementary-material"}A--S3C). To further evaluate the effect of SFAs on lysosome function and other lysosomal degradation pathways, we examined degradation of EGFR, which can be degraded through the endocytosis-lysosomal pathway in response to EGF ([@bib1], [@bib72]) ([Figure S3](#mmc1){ref-type="supplementary-material"}D). C18:0 did not influence EGF-induced lysosomal EGFR degradation, whereas bafilomycin A1 blocked degradation of EGFR after EGF treatment in VSMCs. These results revealed that SFAs do not affect lysosome function but inhibit autophagy prior to autolysosome formation. We next generated VSMCs stably expressing GFP-Syntaxin 17 (GFP-STX17), a matured autophagosome marker ([@bib21], [@bib72], [@bib73], [@bib78]), to examine which step of autophagy is affected by SFAs. Based on the immunofluorescence analysis, unlike bafilomycin A1, SFA treatment significantly reduced co-localizations between Lc3 and STX17 ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F) and between Lc3 and Lamp1 ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3G), whereas STX17 and Lamp1 double-negative Lc3 was significantly increased in VSMCs treated with C18:0 ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3H). These results suggest that SFAs block a step that occurs prior to mature autophagosome formation.

SFAs Induce Abnormal Formation of DFCP1/WIPI2-Positive Omegasomes and Accumulation of Isolation Membranes {#sec2.5}
---------------------------------------------------------------------------------------------------------

We expect that SFAs inhibit autophagy machinery at a step prior to formation of the mature autophagosome. Formation of omegasomes is an early event of autophagosome generation. To determine whether SFAs influence omegasome formation and structures, we generated VSMCs stably expressing GFP-DFCP1 and analyzed them with confocal microscopy ([Figure 3](#fig3){ref-type="fig"}A). Because DFCP1 localizes on omegasome structures by binding to PI3P, DFCP1 forms punctate-like structures ([@bib4]). In normal VSMCs (vehicle treatment), DFCP1 formed punctate-like structures in a large proportion (97.1%) and punctates with long tube-like structures in a small proportion (2.9%) ([Figures 3](#fig3){ref-type="fig"}A and 3B). Surprisingly, on the other hand, C18:0 treatment induced abnormally enlarged DFCP1 structures that formed large ring shapes similar to the letter Ω and long tube shapes with branches in over 95% of VSMCs, whereas less than 5% showed normal punctate-like structures ([Figures 3](#fig3){ref-type="fig"}A and 3B). To confirm that SFAs induce abnormally enlarged omegasome formation, we examined the structures of omegasomes using endogenous WIPI2, another omegasome marker, and analyzed co-localization with Lc3 in VSMCs treated with C18:0 ([Figure 3](#fig3){ref-type="fig"}C). WIPI2 formed normal punctate structures in VSMCs treated with vehicle. Similar to DFCP1-postive membranes, C18:0 treatment drastically induced abnormal enlargement of WIPI2-positive omegasomes ([Figures 3](#fig3){ref-type="fig"}C and 3D). In addition, Lc3 was more significantly accumulated on WIPI2-positive membranes in VSMCs treated with C18:0 than VSMCs treated with vehicle ([Figures 3](#fig3){ref-type="fig"}C and 3E), suggesting accumulation of unclosed immature autophagosomes (isolation membranes) in the omegasomes. To confirm the accumulation of isolation membranes, we used ATG16L1 as an isolation membrane-specific marker. VSMCs treated with C18:0 had significantly higher DFCP1-postive ATG16L1 punctates ([Figures 3](#fig3){ref-type="fig"}F and 3G). Consistent with detailed confocal immunofluorescence analyses, electron microscopy analysis revealed that accumulation of abnormal enlarged membrane structures and isolation membranes was specifically observed in VSMCs treated with C18:0 ([Figure 3](#fig3){ref-type="fig"}H). We next examined whether the modulations of PI3 kinase- (Vps34) and PI3P phosphatase- (myotubularin-related phosphatase, Mtmr) mediated PI3P homeostasis contribute to SFA-induced omegasome formation. The total amount of PI3P was not changed in C18:0-treated VSMCs ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Abnormal omegasome formation by C18:0 treatment was significantly attenuated by the inhibition of a PI3 kinase, VPS34 ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). In addition, unlike C18:0 treatment, the modulation of PI3P by the overexpression of VPS34-FLAG or the knockdown of Mtmr did not induce abnormal DFCP1-positive omegasome formation in VSMCs ([Figures S4](#mmc1){ref-type="supplementary-material"}D, S4E, and [Table S1](#mmc1){ref-type="supplementary-material"}). Two studies consistently reported that autophagy-related Mtmr-6, -8, and -9 did not induce abnormal omegasome formation ([@bib53], [@bib82]). These data suggest that modulations of Vps34 and Mtmr-regulated PI3P did not contribute to SFA-induced abnormal omegasome formation. SFA-induced abnormal omegasome formation and accumulation of isolation membranes occurred not only in VSMCs but also in HeLa cells ([Figures S4](#mmc1){ref-type="supplementary-material"}F--S4H). These data suggest that SFAs lead to abnormal formation of omegasomes, resulting in accumulation of Lc3-II-anchored isolation membranes, which is a common effect of SFAs.Figure 3SFAs Lead to Abnormal Formation of DFCP1/WIPI2-Positive Omegasomes and Accumulation of Lc3 in VSMCs(A) Confocal microscopy images of GFP-DFCP1 (green) in fixed stable VSMCs expressing GFP-DFCP1 treated with EBSS and BSA (Veh) or 200 μM C18:0 (SFA) for 2 h. Scale represents 10 μm. Arrow indicates enlarged tube and ring structure of GFP-DFCP1 with a Ω shape.(B) Percentage of VSMCs with one or more enlarged GFP-DFCP1 structures in analysis of [Figure 3](#fig3){ref-type="fig"}A. (n = 3, from 35 cells in each experiment; 2-tailed Student\'s t test). ∗p \< 0.05. Data are represented as mean ± SEM.(C) Confocal microscopy images of endogenous WIPI2 (green) and Lc3 (red) in wild-type VSMCs treated with EBSS and Veh or SFA for 2 h. Scale represents 10 μm. Arrow indicates enlarged WIPI2 and arrowhead indicates WIPI2-positive Lc3.(D) Percentage of VSMCs with enlarged WIPI2 structures (n = 3, from 33 cells in each experiment; 2-tailed Student\'s t test). ∗p \< 0.05. Data are represented as mean ± SEM.(E) Number of Lc3 punctation with WIPI2 (n = 22, 2-tailed Student\'s t test). ∗p \< 0.05. Data are represented as mean ± SEM.(F) Confocal microscopy images of GFP-DFCP1 (green) and endogenous ATG16L1 (red) in VSMCs treated with EBSS and Veh or SFA for 2 hr. Scale represents 10 μm. Arrowhead indicates DFCP1-positive ATG16L1.(G) Number of ATG16L1 punctation with GFP-DFCP1 (n = 26, 2-tailed Student\'s t test). ∗p \< 0.05. Data are represented as mean ± SEM.(H) Electron micrography in wild-type VSMCs treated with EBSS and Veh or SFA for 2 h.Scale represents 1 μm. Asterisk indicates enlarged membrane structure, arrowhead indicates unclosed membrane as isolation membrane, and arrow indicates Ω-like structure. ER, endoplasmic reticulum Mt, mitochondria; AP, autophagosome; AL, autolysosome; Nuc, nucleus.

Characterization of SFA-Induced Abnormal Formation of Omegasomes {#sec2.6}
----------------------------------------------------------------

To examine how SFAs induce the abnormal formation of omegasomes, we captured a live image of VSMCs expressing GFP-DFCP after SFA treatment. As shown in [Video S1](#mmc2){ref-type="supplementary-material"}, the peak of SFA-induced abnormal formation of omegasomes occurred between 0.5 and 1 h after C18:0 treatment. Five major characteristics of abnormal omegasome formation were detected ([Video S1](#mmc2){ref-type="supplementary-material"} and [Figure S4](#mmc1){ref-type="supplementary-material"}): (1) enlargement: a single omegasome is simply enlarged ([Figure S4](#mmc1){ref-type="supplementary-material"}I); (2) multiplication: an original omegasome produces another omegasome, which produces another omegasome ([Figure S4](#mmc1){ref-type="supplementary-material"}J); (3) elongation: the omegasome membrane is simply elongated ([Figure S4](#mmc1){ref-type="supplementary-material"}K); (4) clusterization: multiple omegasomes approach each other and form a cluster ([Figure S4](#mmc1){ref-type="supplementary-material"}L); (5) fusion: some of the omegasome clusters fuse and generate a single large omegasome ([Figure S4](#mmc1){ref-type="supplementary-material"}M). These abnormal omegasome formations were not observed in VSMCs treated with vehicle ([Video S2](#mmc3){ref-type="supplementary-material"}).

Video S1. Time Lapse Imaging of SFA-induced Abnormal Omegasome Formation in Stable VSMCs Expressing GFP-DFCP1, Related to Figure 3Images of stable VSMCs expressing GFP-DFCP1 treated with 200 μM C18:0 (SFA) were acquired at 1 frame per 5.58 s for 27.5 min under EBSS conditions. Scale represents 5 μm and time indicates time elapsed after SFA treatment. SFA-induced abnormal characteristics of omegasomes (enlargement, multiplication, elongation, clusterization, and fusion) are indicated by white dotted squares, related to Figure S4I--S4M

Video S2 Time Lapse Imaging of Omegasome Formation in Stable VSMCs Expressing GFP-DFCP1 under Vehicle Treatment, Related to Figure 3Images of stable VSMCs expressing GFP-DFCP1 were acquired at 1 frame per 5.58 s for 18.5 min under EBSS conditions or BSA (vehicle) conditions. Scale represents 5 μm and time indicates time elapsed after EBSS treatment. Normal omegasome formation, in which punctate-like structure appears and then quickly disappears under starvation (white dotted squares). Most GFP-DFCP1s are localized in the Golgi body on the right side of the video image, consistent with Figure S5A (GFP-DFCP1 co-localized with the Golgi marker RCAS1)

Gpat4 Mediates Accumulation of Lc3 and Enlargement of WIPI2-Positive Omegasomes through SFA Treatment {#sec2.7}
-----------------------------------------------------------------------------------------------------

To examine whether free SFAs or SFA-derived metabolites affect autophagy, we first modified acyl-CoA synthetase (ACS) with Triacsin C, an inhibitor of ACS. Triacsin C treatment completely blocked the incorporation of fatty acids into acyl lipids ([Figure 4](#fig4){ref-type="fig"}A). In the presence of Triacsin C, C18:0 treatment no longer increased levels of autophagic substrates such as Lc3b-II and p62 ([Figure 4](#fig4){ref-type="fig"}B). These data suggest that SFAs must be incorporated into an acyl-lipid to inhibit autophagic flux. We therefore next examined which acyltransferase contributes to SFA-mediated autophagy inhibition using an shRNA-mediated acyltransferase knockdown (KD) VSMC library that we previously generated ([@bib43]) ([Figure 4](#fig4){ref-type="fig"}C). Each acyltransferase KD VSMC was treated with C18:0 for 2 h. Similar to [Figures 1](#fig1){ref-type="fig"}F and 1G, C18:0 treatment significantly induced accumulation of Lc3 puncta compared with vehicle. Interestingly, *Gpat4* and *Agpat3* KD reciprocally regulated SFA-induced accumulation of Lc3 in VSMCs ([Figures 4](#fig4){ref-type="fig"}C and 4D). *Gpat4* KD reduced SFA-induced Lc3 puncta accumulation by 79%, whereas *Agpat3* knockdown significantly increased the number of Lc3 puncta in the presence of SFAs. In addition, immunoblot analysis confirmed that *Gpat4* KD reduced levels of Lc3b-II increased with C18:0 treatment, whereas *Agpat3* KD increased levels ([Figure 4](#fig4){ref-type="fig"}E). We next examined whether *Gpat4* contributes to SFA-induced abnormal enlargement of WIPI2-positive omegasomes and accumulation of isolation membranes. *Gpat4* KD reduced levels of abnormally enlarged WIPI2 membranes and accumulation of Lc3 on WIPI2-positive omegasomes under SFA treatment, suggesting that *Gpat4* mediates SFA-induced abnormal enlargement of omegasomes, leading to accumulation of Lc3-positive isolation membranes ([Figures 4](#fig4){ref-type="fig"}F--4H). To analyze the effect of Gpat4 knockdown on SFA-induced autophagic flux inhibition, stable VSMCs expressing GFP-LC3-RFP-LC3ΔG probe were transfected with Gpat4 siRNA and then treated with SFAs under starvation conditions. Gpat4 siRNA treatment significantly reduced levels of Gpat4 in VSMCs by 88% ([Figure 4](#fig4){ref-type="fig"}I). Gpat4 knockdown significantly attenuated autophagic flux inhibition by C18:0 compared with scrambled siRNA ([Figure 4](#fig4){ref-type="fig"}J).Figure 4Gpat4 Mediates Accumulation of Lipidated Lc3 and Abnormal Formation of WIPI2-Positive Omegasomes by SFAs(A) Scheme of fatty acid metabolism with acyl-CoA synthetase (ACS), Gpat4, and Agpat3. TriacsinC: an acyl-CoA synthetase inhibitor.(B) Immunoblot analysis of VSMCs treated with 250 μM C18:0 with or without 10 μM Triacsin C for 6 h.(C) Number of Lc3 punctations in shRNA-based acyltransferase knockdown (KD) VSMCs treated with BSA (Veh) or 200 μM C18:0 for 6 h under complete media conditions (n = 4, one-way ANOVA). ∗∗∗p \< 0.001 versus Empty shRNAVeh. \#\#\#p \< 0.001 versus Empty shRNA SFA. Data are represented as mean ± SEM.(D) Immunofluorescence of Lc3 (red) and DAPI (blue) in empty, *Gpat4* and *Agpat3* KD VSMCs treated with 200 μM C18:0 for 6 h under complete media conditions. Scale represents 10 μm.(E) Immunoblot analysis of *Gpat4* or *Agpat3* KD VSMCs treated with Veh or 250 μM C18:0 for 6 h under complete media conditions.(F) Immunofluorescence of endogenous WIPI2 (green) and Lc3 (red) in empty and *Gpat4* KD VSMCs treated with Veh or 200 μM C18:0 for 2 h under complete media conditions. Arrow indicates enlarged WIPI2 and arrowhead indicates WIPI2-positive Lc3 punctation. Scale represents 10 μm.(G) Percentage of VSMCs with enlarged WIPI2 structures (n = 3, from 33 cells in each experiment; 2-tailed Student\'s t test). ∗p \< 0.05. Data are represented as mean ± SEM.(H) Number of Lc3 punctation with WIPI2 from [Figure 4](#fig4){ref-type="fig"}F analysis (n = 15, one-way ANOVA). ∗p \< 0.05; N.S., not significant. Data are represented as mean ± SEM.(I) Levels of Gpat4 mRNA by qRT-PCR in 50 nM negative control or Gpat4 siRNA-transfected VSMCs. (n = 3, 2-tailed Student\'s t test). ∗p \< 0.05. Data are represented as mean ± SEM.(J) Measurement of autophagic flux with Gpat4 knockdown. Stable VSMCs expressing GFP-LC3-RFP-LC3ΔG were transfected with 50 nM negative control or Gpat4 siRNA. After 24 h, VSMCs were co-treated with Veh or 500 μM C18:0 under starvation conditions for 6 h. GFP/RFP ratio data was expressed as fold value against Veh (n = 6, one-way ANOVA). ∗p \< 0.05.

Saturated LPAs Induce Autophagic Flux by Inducing Abnormal Formation of DFCP1-Positive Omegasomes {#sec2.8}
-------------------------------------------------------------------------------------------------

Gpat4 and Agpat3 catalyze the initial two steps of glycerolipid synthesis ([@bib13]). Gpat4 is the first enzyme to catalyze the conversion of glycerol-3-phosphate to 1-acyl-lysophosphatidic acid (LPA), which is further acylated by Agpat3 to generate phosphatidic acid (PA) ([Figure 4](#fig4){ref-type="fig"}A). Our previous lipidomic study revealed that abnormally excessive amounts of fully saturated LPAs (i.e 18:0-LPA) in addition to fully saturated PAs (i.e. 18:0/18:0-PA) were accumulated in the aortic medias of SMC-*Scd1/2* KO mice and cultured VSMCs treated with SFAs ([@bib43]). We therefore hypothesized that accumulation of saturated LPAs, LPAs derived from SFAs, mediate inhibition of autophagic flux. To confirm our hypothesis, we treated VSMCs with an SFA (C18:0), saturated and unsaturated LPAs (18:0-LPA and 18:1-LPA), and fully saturated and fully unsaturated PAs (18:0/18:0-PA and 18:1/18:1-PA). The immunoblot analysis with Lc3b-II shows that 18:0-LPA but not 18:1-LPA dose-dependently induced accumulation of Lc3b-II ([Figure 5](#fig5){ref-type="fig"}A). However, treatment with 18:0-LPA was unable to activate ER stress signals such as ATF4, CHOP, and BiP ([Figure 5](#fig5){ref-type="fig"}B). Unlike C18:0 and 18:0-LPA, both 18:0/18:0-PA and 18:1/18:1-PA did not induce accumulation of Lc3b-II ([Figure 5](#fig5){ref-type="fig"}C). In addition, treatment with 18:0/18:0-PA did not affect total amounts of 18:0-LPA in VSMCs ([Figure 5](#fig5){ref-type="fig"}D). To confirm that 18:0-LPA inhibits autophagic flux similar to SFAs, VSMCs expressing GFP-LC3-RFP-LC3ΔG probe were treated with 18:0-LPA. 18:0-LPA treatment significantly increased the ratio of GFP/RFP fluorescence, indicating that 18:0-LPA inhibits autophagic flux ([Figure 5](#fig5){ref-type="fig"}E). To evaluate whether 18:0-LPA modulates DFCP1-positive membrane structures, we perfomed confocal microscopy analysis with stable GFP-DFCP1 VSMCs treated with 18:0-LPA and 18:0/18:0-PA ([Figures 5](#fig5){ref-type="fig"}F and 5G). DFCP1 formed enlarged structures under 18:0-LPA treatment, similar to C18:0 treatment, whereas 18:0/18:0-PA did not induce enlargement of DFCP1-postive membrane structures. Electron microscopy analysis confirmed abnormally enlarged membrane structures in VSMCs treated with 18:0-LPA but not in VSMCs treated with vehicle ([Figure 5](#fig5){ref-type="fig"}H).Figure 5Saturated LPAs, but Not Fully Saturated PAs, Induce Accumulation of Lipidated Lc3b-II and Abnormal Enlargement of DFCP1-Positive Omegasomes in VSMCs(A) Immunoblot analysis of VSMCs treated with BSA (−), C18:0, 18:0-LPA, 18:1-LPA, or bafilomycin A1 under EBSS conditions for 2 h.(B) Immunoblot analysis of ER stress proteins in VSMCs treated with BSA (−), C18:0, or 18:0-LPA under complete media conditions for 6 h.(C) Immunoblot analysis of VSMCs treated with BSA (−), C18:0, 18:0/18:0-PA, 18:1/18:1-PA, or bafilomycin A1 under EBSS conditions for 2 h.(D) LC-MS-based absolute levels of 18:0-LPA species of VSMCs after 6 h of treatment with 300 μM C18:0, 100 μM 18:0-LPA, or 100 μM 18:0/18:0-PA (n = 3, one-way ANOVA). ∗p \< 0.05. Data are represented as mean ± SEM.(E) Measurement of autophagic flux using stable VSMCs expressing GFP-LC3-RFP-LC3ΔG treated with BSA (Veh), 300 μM C18:0, 100 μM 18:0-LPA, or 200 nM bafilomycin A1 under EBSS conditions for 6 h. GFP/RFP ratio data were expressed as fold value against vehicle (n = 6, one-way ANOVA). ∗p \< 0.05.(F) Confocal microscopy images in stable VSMCs expressing GFP-DFCP1 treated with EBSS and Veh, 200 μM C18:0, 100 μM 18:0-LPA, or 100 μM 18:0/18:0-PA for 2 h. Scale represents 20 μm and arrow indicates VSMCs with enlarged GFP-SFCP1 structures.(G) Percentage of VSMCs with enlarged GFP-DFCP1 structures in [Figure 5](#fig5){ref-type="fig"}F analysis (n = 3, from 33--34 cells in each experiment, one-way ANOVA). ∗p \< 0.05. Data are represented as mean ± SEM.(H) Electron micrograph of wild-type VSMCs co-treated with 100 μM 18:0-LPA and EBSS for 2 h. Scale represents 1 μm. Asterisk indicates enlarged membrane structure. ER, endoplasmic reticulum Mt, mitochondria; Nuc, nucleus.

SFAs Accumulate as Saturated LPAs in the Contact Sites between DFCP1-Positive Omegasomes and Mitochondria-Associated Membranes {#sec2.9}
------------------------------------------------------------------------------------------------------------------------------

To determine which organelle is responsible for abnormal formation of omegasomes by SFAs, we performed immunostaining of various organelle markers in GFP-DFCP1 cells ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). Normally, DFCP1 co-localizes with a golgi marker, RCAS1, at the close region of the nucleus ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Although enlarged DFCP1-postive omegasomes in VSMCs treated with C18:0 do not localize with either RCAS1, a lysosomal marker Lamp1, or lipid droplets stained with LipidTox Red ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B), they are located in the close vicinity of an ER marker, Calnexin, and a mitochondria marker, Tomm20 ([Figure S5](#mmc1){ref-type="supplementary-material"}A, magnified images). In addition, abnormally enlarged DFCP1 was localized next to other ER markers, KDEL and Tomm20, suggesting that abnormally enlarged omegasomes are possibly associated with contact sites between the ER and mitochondria ([Figure S5](#mmc1){ref-type="supplementary-material"}C). The contact sites between ER-mitochondria and DFCP1 were significantly increased in VSMCs treated with C18:0 ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D). Moreover, electron micrographs of SFA-treated VSMCs showed that most of the enlarged membrane structures were connected to the contact sites of the ER and mitochondria ([Figure 6](#fig6){ref-type="fig"}A). ER membranes and mitochondria membranes form mitochondria-associated membranes (MAMs), which play many physiological roles such as autophagosome formation with the Beclin-1-Vps34 complex ([@bib17]). In addition, the MAM is a major site of glycerolipid synthesis ([@bib41], [@bib75]). DFCP1 proteins are translocated to the MAM under starvation ([@bib17]). To determine tight associations between abnormally enlarged DFCP1-positive omegasomes and the MAM, we prepared MAM fractions from vehicle- and SFA-treated VSMCs ([Figure 6](#fig6){ref-type="fig"}B). The immunoblot analysis shows that MAM fractions from both vehicle- and SFA-treated VSMCs expectedly contain MAM markers such as Calnexin and Facl4 proteins. Furthermore, PI3K complexes such as Beclin and Vps34 were present in MAM fractions. In the MAM of SFA-treated VSMCs, levels of DFCP1 protein were increased compared with those from vehicle-treated VSMCs ([Figure 6](#fig6){ref-type="fig"}B), consistent with the confocal analysis shown in [Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D. Next, we profiled the amount of lysophosphatidic acid species in MAM fractions using an LC/MS-based measurement ([Figure 6](#fig6){ref-type="fig"}C). Levels of 18:0-LPA were significantly increased by 14-fold in the MAM from VSMCs treated with C18:0 compared with vehicle. Because MAM fractions from VSMCs treated with C18:0 contain significant amounts of DFCP1, the elevation of 18:0-LPA could be associated with abnormally enlarged DFCP1-membranes. Therefore, we next performed OptiPrep-fractionation to isolate DFCP1-positive membranes ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). Immunoblot analysis showed that GFP-DFCP1 protein was mainly detected on fractions 11, 12, 13, and 14 in both vehicle- and SFA-treated VSMCs ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Because only fraction 11 of SFA-treated VSMCs contains Lc3b-II, Tomm20, and Calnexin proteins, we used fraction 11 as a DFCP1-enriched membrane fraction. LC/MS analysis showed that levels of 18:0-LPA increased by 6-fold in DFCP1-enriched membranes from VSMCs treated with C18:0 ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Interestingly, endogenous Gpat4 protein was detected in MAM fractions from both control and C18:0-treated VSMCs ([Figure 6](#fig6){ref-type="fig"}B). To examine whether Gpat4 localizes in the contact site of the MAM and DFCP1 membranes to generate 18:0-LPA as a source of membrane lipids, we analyzed VSMCs overexpressing GFP-DFCP1 and GPAT4-tdTomato by confocal microscopy. As shown in [Figures 7](#fig7){ref-type="fig"}A and 7B, SFA treatment showed an increased number of GPAT4 close to the double-positive sites of Tomm20 and DFCP1. In addition, over 85% of Lc3 puncta are observed in proximity with GPAT4 in VSMCs ([Figures S6](#mmc1){ref-type="supplementary-material"}C--S6E). These data suggest that Gpat4 might localize at the MAM and autophagosome formation sites and maybe one of the enzymes indirectly providing lipids for omegasome formation and enlargement. To confirm that DFCP1-omegasomes associated with the MAM are the site of isolation membrane formation and accumulation in VSMCs treated with C18:0 and 18:0-LPA, we performed immunofluorescence analysis to analyze the co-localization of GFP-DFCP1 with Lc3 and Tomm20 ([Figures 7](#fig7){ref-type="fig"}C and 7D). Lc3 puncta were more accumulated on the DFCP1 membrane next to Tomm20-positive signals in C18:0- and 18:0-LPA-treated VSMCs than in vehicle-treated VSMCs.Figure 6SFAs Lead to Accumulation of Saturated LPAs on Mitochondria-Associated Membrane (MAM) Contact Sites with DFCP1-Positive Omegasomes in VSMCs(A) Electron micrograph of wild-type VSMCs co-treated with 200 μM C18:0 and EBSS for 2 h. Scale represents 1 μm or 500 nm in the magnified image. Asterisk indicates enlarged membrane structure and arrow indicates connections between enlarged membrane and ER, mitochondria, or ER-mitochondria contact site. ER, endoplasmic reticulum Mt, mitochondria; Nuc, nucleus.(B) Immunoblot analysis of post nuclear supernatant (PNS), microsome (Micro), cytosol (Cyto), mitochondria (Mito), and MAM fractions of stable VSMCs expressing GFP-DFCP1 co-treated with EBSS and BSA (Veh) or C18:0 (SFA) for 2 h.(C) LC-MS-based absolute levels of LPA species of purified MAM fractions (n = 3, 2-tailed Student\'s t test). ∗p \< 0.05. Data are represented as mean ± SEM.Figure 7SFAs Increase GPAT4 Localized in Close Proximity to the Double-Positive Site of Tomm20 and DFCP1 Omegasome in VSMCs(A) Confocal microscopy images of Tomm20 (magenta), GFP-DFCP1 (green), or GPAT4-tdTomato (GPAT4-T) (red) in VSMCs stably expressing GFP-DFCP1 and GPAT4-tdTomato treated with Veh or SFA under EBSS conditions for 2 h. Scale represents 10 μm. Arrow indicates Tomm20, GFP-DFCP1, and GPAT4-tdTomato contact sites.(B) Number of GFP-DFCP1-GPAT4-Tomm20 contact sites (n = 16, 2-tailed Student\'s t test). ∗p \< 0.05. Data are represented as mean ± SEM.(C) Confocal microscopy images of Tomm20 (magenta), GFP-DFCP1 (green), and Lc3 (red) in stable VSMCs expressing GFP-DFCP1 co-treated with Veh, C18:0, or 18:0-LPA under EBSS conditions for 2 h. Scale represents 10 μm. Arrow indicates Tomm20, DFCP1, and Lc3-contact site.(D) Number of GFP-DFCP1-Lc3-Tomm20 contact sites in [Figure 7](#fig7){ref-type="fig"}C (n = 20, One-way ANOVA). ∗p \< 0.05. Data are represented as mean ± SEM.

Unsaturated LPAs Block SFA-Induced Abnormal Enlargement of DFCP1-Positive Omegasomes, Accumulation of Lipidated Lc3, and Calcification in VSMCs {#sec2.10}
-----------------------------------------------------------------------------------------------------------------------------------------------

UFAs attenuate SFA-induced lipotoxicity ([@bib36], [@bib44], [@bib43]). We examined whether co-treatment of unsaturated LPA (18:1-LPA) blocks SFA-induced abnormal formation of GFP-DFCP1 structures using confocal microscopy ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B). UFAs (C18:1) significantly blocked SFA-induced enlargement of DFCP1 membranes. Co-treatment with 18:1-LPA also reduced SFA-induced abnormally enlarged GFP-DFCP1 structures ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B). In contrast, fully unsaturated PAs (18:1/18:1-PA) did not influence SFA-induced enlargement of GFP-DFCP1 omegasomes. In the immunoblot analysis, C18:1 inhibited SFA-induced accumulation of Lc3b-II ([Figure S7](#mmc1){ref-type="supplementary-material"}C). Similarly, 18:1-LPA also dose-dependently inhibited C18:0-induced Lc3b-II accumulation ([Figure S7](#mmc1){ref-type="supplementary-material"}D). LPA is a signaling metabolite that works through lysophosphatidic acid receptors (LPARs) in plasma membranes. To study whether the effect of 18:1-LPA occurs via LPARs, VSMCs were treated with LPAR inhibitors such as Brp-LPA, AM095, and H2L5186303 in the presence of 18:1-LPA and C18:0. However, none of the LPAR inhibitors affected the effects of C18:0 and LPA on autophagy ([Figure S7](#mmc1){ref-type="supplementary-material"}E). These results suggest that effects of SFAs and LPAs on the modulation of Lc3b-II are not dependent on LPA receptor signaling.

Gpat4-Generated Saturated LPAs Elicit Lipotoxic Effects In Vitro and In Vivo {#sec2.11}
----------------------------------------------------------------------------

We next examined whether 18:0-LPA mediates SFA-induced lipotoxicities such as VSMC mineralization and apoptosis. Similar to C18:0, 18:0-LPA significantly increased levels of matrix calcium in VSMCs, whereas supplementation with 18:1-LPA, similar to C18:1, reduced mineralization ([Figures 8](#fig8){ref-type="fig"}A--8D) and levels of the cleavage (active) form of caspase 3 induced by C18:0 treatment ([Figure 8](#fig8){ref-type="fig"}E). To study SFA-mediated lipotoxicity through Gpat4-mediated saturated LPA production *in vivo*, we crossed SMC-*Scd1/2* KO mice with *Gpat4* KO mice to generate SMC-*Scd1/2* KO; *Gpat4* triple KO mice. Consistent with our previous report ([@bib43]), SMC-*Scd1/2*KO mice developed severe aortic medial calcification, vascular apoptosis, and accumulation of autophagic substrates such as p62 and Fam134b2, accompanied by significantly increased levels of saturated LPAs such as 16:0-LPA and 18:0-LPA ([Figures 8](#fig8){ref-type="fig"}F--8J). More importantly, Gpat4 deficiency completely blocked SCD deficiency-induced vascular calcification, apoptosis, and inhibition of autophagy ([Figures 8](#fig8){ref-type="fig"}F--8J). In addition, Gpat4 deficiency completely blocked accumulation of aortic saturated LPAs by SMC-SCD deficiency ([Figure 8](#fig8){ref-type="fig"}J).Figure 8*Gpat4* Knockout Blocked Vascular Calcification in *Scd1/2* Knockout Mice After 5/6 Nephrectomy(A and B) (A) Mineralization and (B) ALP activity of VSMCs co-treated with 2.6 mM Pi and Veh or 18:0-LPA every 2 days for 6 days (n = 6, 2-tailed Student\'s t test). ∗p \< 0.05. Data are represented as mean ± SEM.(C) Alizarin red staining of VSMCs co-treated with Pi and Veh or 18:0-LPA for 6 days.(D) Mineralization of VSMCs co-treated with 2.6 mM Pi and 200 μM C18:0 and BSA, 200 μM C18:1, or 20 μM 18:1-LPA every 2 days for 6 days (n = 6, one-way ANOVA). ∗p \< 0.05. Data are represented as mean ± SEM.(E) Immunoblot analysis of caspase 3 and Gapdh in VSMCs treated with 200 μM C18:0 and BSA, 200 μM C18:1, or 20 μM 18:1-LPA for 16 h. Arrow indicates cleaved (active) form of Caspase-3.(F) Photograph (x10 magnification) of the lesions in aortic arches with von Kossa staining in SMC-*Scd1/2* KO mice and SMC-*Scd1/2* and *Gpat4* triple KO mice. Scale represents 200 μm.(G) Quantitative analysis of calcified lesions in [Figure 8](#fig8){ref-type="fig"}F analysis (n = 8, one-way ANOVA). p\< 0.001. Data are represented as mean ± SEM.(H) Levels of autophagy-specific substrates in the aortic medias of SMC-*Scd1/2* KO; *Gpat4* KO mice.(I and J) (I) Percentage of aortic media apoptosis and (J) levels of LPA in the aortic medias of SMC-*Scd1/2* KO; *Gpat4* KO mice (n = 8, One-way ANOVA). ∗p \< 0.05 versus control, \#p \< 0.05 versus SMC-*Scd1/2* KO, and ∗p \< 0.001. Data are represented as mean ± SEM.(K) A model of SFA-induced vascular calcification through impairment of autophagosome maturation. Excess SFAs created through SCD inhibition and SFA supplementation are converted to saturated LPAs by GPAT4 at the MAM. Accumulation of saturated LPAs in MAM-associated omegasomes disrupts the proper balance of SFA-LPAs and UFA-LPAs, which causes abnormal formation of omegasomes, and excess production and accumulation of Lc3-II-positive isolation membranes, resulting in the inhibition of autophagic flux. Saturated LPA-mediated autophagy inhibition induces vascular apoptosis and calcification. G-3-P; grycerol-3-phosphate, LPA; lysophosphatidic acid.

Discussion {#sec3}
==========

SFA-induced lipotoxicity is mediated by modifications of various pathways including apoptosis, ER stress, autophagy, oxidative stress, cell cycle inflammation, and membrane dynamics ([@bib3], [@bib7], [@bib18], [@bib19], [@bib36], [@bib44], [@bib43], [@bib47], [@bib57], [@bib76]). We previously showed that inhibition of SCD induces aortic medial calcification by accumulating SFA-derived metabolites in VSMCs ([@bib43]). In addition, CKD increases circulating SFAs in humans ([@bib43]). These results suggest that SFA-induced lipotoxicity is a major cause of vascular calcification in CKD. However, which lipotoxic pathway is responsible for the development of vascular calcification is not completely understood. The autophagy-lysosomal degradation pathway is a protective mechanism in various organs against diseases such as neurodegenerative diseases, liver diseases, muscular disorders, and pathogen infections ([@bib11], [@bib34], [@bib40], [@bib64]). In this study we showed direct evidence that autophagy in VSMCs plays a protective role in the pathogenesis of vascular calcification in CKD. CKD and SCD deficiency induced significant accumulation of aortic proteins (Lc3b-II, p62 and Fam134b2) specifically degraded through autophagy. More strikingly, SMC-specific Atg5 deficiency, and therefore inhibition of VSMC autophagy, strongly induces vascular calcification and apoptosis, resulting in significant increases in mortality of CKD mice. These results demonstrate that SFA-mediated autophagy inhibition plays a causative role in vascular calcification.

Due to the lack of detailed autophagic flux and mechanistic studies, the effect of SFAs and SCD on autophagy regulation is controversial ([@bib27], [@bib37], [@bib69], [@bib70]). Most of the conclusions in the previous studies were made based on the results of immunoblot analysis and/or confocal microscopic analysis with LC3B. We therefore made extensive efforts to elucidate the effect of SFAs on autophagic flux and the precise mechanism by which SFAs modulate autophagy machinery. Although VSMCs were mainly used in this study, the mechanisms underlying the modulation of autophagy by SFAs are very similar in any cell type as SFAs also elicit the inhibitory effect of autophagy in two other common cell lines, HeLa and NIH-3T3. In this study, we conclude that SFAs such as C18:0 and C16:0 and the inhibition of SCD both inhibit autophagic flux based on the study using the GFP-LC3-RFP-LC3ΔG probe that enabled us to most accurately analyze it ([@bib25], [@bib78]). We therefore conclude that the accumulation of Lc3b-II and p62 in cells treated with SFAs and in the aortic media of SMC-*Scd1/2* KO mice is due to SFA-induced autophagy inhibition. More importantly, in this study we have elucidated the precise mechanism by which SFAs mediate the inhibition of autophagy and demonstrate that SFA accumulation induces abnormal enlargement of MAM-originated omegasomes, which leads to accumulation of Lc3b-II positive isolation membranes on omegasomes.

We previously reported that GPAT4 is one of the enzymes in SFA-induced lipotoxicity and vascular calcification ([@bib43]), which has also been shown by two recent studies ([@bib59], [@bib81]). In addition, we identified that fully saturated PAs produced by the GPAT4-AGPAT3/5 reaction mediate SFA-induced ER stress However, which SFA metabolite mediates the inhibitory effect of SFAs in autophagy has not been studied. Although SFA-induced ER stress was blocked by the inhibition of three enzymes, Gpat4, Agpat3, and Agpat5 ([@bib43]), SFA-induced autophagy inhibition was inhibited only by Gpat4 inhibition. Interestingly, Agpat3 blockage augments SFA-induced Lc3b accumulation. SFA treatment drastically induces accumulation of saturated LPAs ([@bib43]). Treatment with exogenous 18:0-LPA, a saturated LPA, but not fully saturated PAs such as 18:0/18:0-PA, replicates SFA-induced autophagy inhibition including the inhibition of autophagic flux and the generation of abnormally enlarged omegasomes, suggesting that saturated LPAs are specific SFA metabolites that affect omegasome formation and autophagic flux under excess SFAs. Furthermore, co-treatment with unsaturated LPAs such as 18:1-LPA, but not unsaturated PAs such as 18:1/18:1-PA, attenuates SFA-induced autophagy inhibition. These data demonstrate that Gpat4 converts SFAs to saturated LPAs, disrupting the proper balance of SFA-LPAs and UFA-LPAs (ie, 18:0-LPA/18:1-LPA), causing abnormal enlargement of omegasomes. LPAs containing UFAs are a termination factor for the enlargement of omegasomes. Another interesting finding in this study is that Gpat4 is located in the contact sites between abnormally enlarged omegasomes and the MAM, which are increased by SFAs. The sources of isolation membranes have not been fully defined yet, but they possibly come from the ER, mitochondria, and Golgi, recycling endosomes and the plasma membrane through Atg9-mediated vesicle transport ([@bib16], [@bib32], [@bib42], [@bib56], [@bib62], [@bib63], [@bib77]). In addition, the ER-mitochondria contact site (the MAM) is a major site of autophagosome production ([@bib17]). Furthermore over 85% of autophagosome generation sites (Lc3 positive) are closely co-localized with GPAT4 in the cells treated with C18:0 ([Figures S6](#mmc1){ref-type="supplementary-material"}C--S6E). The ER, mitochondria, and contact sites could directly supply lipids to omegasomes and isolation membranes. In fact, SFA treatment induces accumulation of saturated LPAs in the MAM and DFCP1-enriched membranes. The source of omegasome membrane lipids is also not clear, but our data suggest that glycerophospholipids such as LPAs synthesized on the MAM are also used as a major omegasome lipid source under excess SFAs. Gpat4 on the MAM supplies saturated LPAs, which causes the abnormal enlargement of omegasomes. In addition, exogenous 18:0-LPA induces Lc3 accumulation at the contact site of omegasomes and the MAM ([Figure 7](#fig7){ref-type="fig"}). Although several factors such as PI3P, EPG-6, CapZ, and DFCP1 that influence omegasome formation have been identified ([@bib4], [@bib39], [@bib48], [@bib53]), LPAs such as 18:0-LPA are critical lipid metabolites that affect omegasome formation.

In conclusion, our findings indicate that saturated LPAs could perturb the autophagy machinery. As illustrated in our model ([Figure 8](#fig8){ref-type="fig"}K), we speculate that Gpat4 localizes on the MAM, utilizing excess SFAs by SCD inhibition and increases SFA intake and converts them into saturated LPAs, which are used as a lipid source for omegasome formation. However, excess production of saturated LPAs such as 18:0-LPA unbalances SFA-LPAs and UFA-LPAs on omegasomes, causing abnormal enlargement. Abnormally enlarged omegasomes containing excess saturated LPAs produce and accumulate isolation membranes, block autophagic flux, and cause vascular apoptosis and calcification. We previously reported that fully saturated PAs (i.e. 18:0/18:0-PA) generated through the Gpat4-Agpat3/5 reaction are responsible for SFA-mediated ER stress ([@bib43]). These results suggest that each SFA metabolite mediates a distinct pathway of SFA lipotoxicity. Taken together, Gpat4 could be a major therapeutic target for the treatment of lipotoxicity-induced chronic diseases such as vascular calcification.

Limitations of the Study {#sec3.1}
------------------------

Although artifacts might arise due to the EM sample preparation, abnormal enlarged omegasome structures were only observed in cells treated with SFAs or SFA-LPAs but not vehicles. To ensure the results, the experiments have been at least triplicated. In addition, this study has revealed that GPAT4-generated SFA-LPAs indirectly affect autophagy through the generation of abnormal omegasomes. Follow-up studies will be required to determine whether GPAT4 and SFA-LPAs directly affect autophagosome formation.
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